JP4336451B2 - Ｈｌａ−ｅ結合 - Google Patents

Ｈｌａ−ｅ結合 Download PDF

Info

Publication number
JP4336451B2
JP4336451B2 JP2000523554A JP2000523554A JP4336451B2 JP 4336451 B2 JP4336451 B2 JP 4336451B2 JP 2000523554 A JP2000523554 A JP 2000523554A JP 2000523554 A JP2000523554 A JP 2000523554A JP 4336451 B2 JP4336451 B2 JP 4336451B2
Authority
JP
Japan
Prior art keywords
hla
cells
nkg2
cell
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000523554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513541A5 (enExample
JP2002513541A (ja
Inventor
ヴェロニク エム ブラウド，
デヴィッド エス ジェイ アラン，
グラハム エス オッグ，
クリストファー エー オカラガン，
アンドリュー ジェイ マクマイケル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of JP2002513541A publication Critical patent/JP2002513541A/ja
Publication of JP2002513541A5 publication Critical patent/JP2002513541A5/ja
Application granted granted Critical
Publication of JP4336451B2 publication Critical patent/JP4336451B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
JP2000523554A 1997-12-04 1998-12-04 Ｈｌａ−ｅ結合 Expired - Lifetime JP4336451B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
GB9725764.6 1997-12-04
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008314107A Division JP4437160B2 (ja) 1997-12-04 2008-12-10 Ｈｌａ−ｅ結合

Publications (3)

Publication Number Publication Date
JP2002513541A JP2002513541A (ja) 2002-05-14
JP2002513541A5 JP2002513541A5 (enExample) 2006-01-19
JP4336451B2 true JP4336451B2 (ja) 2009-09-30

Family

ID=10823165

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000523554A Expired - Lifetime JP4336451B2 (ja) 1997-12-04 1998-12-04 Ｈｌａ−ｅ結合
JP2008314107A Expired - Lifetime JP4437160B2 (ja) 1997-12-04 2008-12-10 Ｈｌａ−ｅ結合
JP2009191564A Expired - Lifetime JP5268828B2 (ja) 1997-12-04 2009-08-21 Ｈｌａ−ｅ結合
JP2013006244A Abandoned JP2013081478A (ja) 1997-12-04 2013-01-17 Ｈｌａ−ｅ結合

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2008314107A Expired - Lifetime JP4437160B2 (ja) 1997-12-04 2008-12-10 Ｈｌａ−ｅ結合
JP2009191564A Expired - Lifetime JP5268828B2 (ja) 1997-12-04 2009-08-21 Ｈｌａ−ｅ結合
JP2013006244A Abandoned JP2013081478A (ja) 1997-12-04 2013-01-17 Ｈｌａ−ｅ結合

Country Status (7)

Country Link
US (3) US7410767B1 (enExample)
EP (2) EP1036327B1 (enExample)
JP (4) JP4336451B2 (enExample)
AT (1) ATE438096T1 (enExample)
DE (1) DE69841020D1 (enExample)
GB (1) GB9725764D0 (enExample)
WO (1) WO1999028748A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1423140A2 (en) * 2001-07-31 2004-06-02 Karl Petter Söderström Compositions and methods for modulation of immune responses
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1664110B1 (en) * 2003-08-26 2008-08-20 Danmarks Tekniske Universitet A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP1781313A4 (en) 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
AU2014248605B2 (en) * 2013-03-12 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for modification of HLA
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2015148960A1 (en) * 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
EP3193931B1 (en) 2014-09-16 2020-08-05 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
KR102598068B1 (ko) 2014-10-23 2023-11-06 이나뜨 파르마 에스.에이. 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN111801348A (zh) * 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
SG11202105480WA (en) * 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CA3197662A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
EP4388012A4 (en) * 2021-08-20 2025-09-17 Univ Duke ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES
WO2024036303A2 (en) * 2022-08-11 2024-02-15 The Trustees Of The University Of Pennsylvania Universal t cells and compositions and methods of use thereof
EP4688859A1 (en) * 2023-03-24 2026-02-11 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
WO2026016730A1 (zh) * 2024-07-17 2026-01-22 广州瑞风生物科技股份有限公司 一种突变hla-e重链、hla-e三聚体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
JP2013081478A (ja) 2013-05-09
JP2010024233A (ja) 2010-02-04
JP2009106299A (ja) 2009-05-21
JP5268828B2 (ja) 2013-08-21
US7410767B1 (en) 2008-08-12
GB9725764D0 (en) 1998-02-04
WO1999028748A3 (en) 1999-12-23
WO1999028748A2 (en) 1999-06-10
EP1036327A2 (en) 2000-09-20
US20150361180A1 (en) 2015-12-17
JP4437160B2 (ja) 2010-03-24
DE69841020D1 (de) 2009-09-10
JP2002513541A (ja) 2002-05-14
US20080274475A1 (en) 2008-11-06
EP2144065A1 (en) 2010-01-13
EP1036327B1 (en) 2009-07-29
ATE438096T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
JP5268828B2 (ja) Ｈｌａ−ｅ結合
US20250312446A1 (en) Methods and compositions for adoptive cell therapy
US12139526B2 (en) Modified chimeric receptors and related compositions and methods
AU2016349724B2 (en) Chimeric receptors containing TRAF-inducing domains and related compositions and methods
JP2021534802A (ja) 複数のｈｌａ−ｇアイソフォームに対するキメラ抗原レセプター
Wiendl et al. The non‐classical MHC molecule HLA‐G protects human muscle cells from immune‐mediated lysis: implications for myoblast transplantation and gene therapy
Man et al. Role of endogenous peptide in human alloreactive cytotoxic T cell responses
HK40045337A (en) Methods and compositions for adoptive cell therapy
Tu Ly49 receptors and MHC-I interactions, and their implications in cancer immunosurveillance
HK1261191A1 (en) Modified chimeric receptors and related compositions and methods
HK1261191B (en) Modified chimeric receptors and related compositions and methods
Mbiribindi Nvunabandi Impact of the Major Histocompatibility Complex class I peptide repertoire on Natural Killer cell function
Foley The immunogenetics of natural killer cell alloreactivity
HK1244826B (en) Methods and compositions for adoptive cell therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090623

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090629

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120703

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120703

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130703

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term